Skip to main content
SpringerLink
Log in

Moyamoya Syndrome

  • Chapter
  • First Online:
Moyamoya Disease: Current Knowledge and Future Perspectives

Abstract

Moyamoya syndrome refers to the presence of an underlying condition in addition to the angiographic findings of moyamoya disease. The diseases which may accompany moyamoya disease and therefore classify a patient as suffering from moyamoya syndrome are wide-ranging and are not uniformly recognized in international comparison. This chapter will focus on the epidemiology in Asia, Europe, and North America. The most frequent underlying conditions reported in patients with moyamoya syndrome will be discussed, as well as their possible pathophysiological links to moyamoya disease. Finally, an overview of long-term outcomes following surgical intervention as well as new perspectives in patient care will be given.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969;20(3):288–99.

    Article  CAS  PubMed  Google Scholar 

  2. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245–66.

    Article  Google Scholar 

  3. Hayashi K, Horie N, Izumo T, Nagata I. Nationwide survey on quasi-moyamoya disease in Japan. Acta Neurochir. 2014;156(5):935–40.

    Article  PubMed  Google Scholar 

  4. Hayashi K, Horie N, Suyama K, Nagata I. An epidemiological survey of moyamoya disease, unilateral moyamoya disease and quasi-moyamoya disease in Japan. Clin Neurol Neurosurg. 2013;115(7):930–3.

    Article  PubMed  Google Scholar 

  5. Wei Y-C, Liu C-H, Chang T-Y, Chin S-C, Chang C-H, Huang K-L, et al. Coexisting diseases of moyamoya vasculopathy. J Stroke Cerebrovasc Dis. 2014;23(6):1344–50.

    Article  PubMed  Google Scholar 

  6. Zhao M, Lin Z, Deng X, Zhang Q, Zhang D, Zhang Y, et al. Clinical characteristics and natural history of quasi-moyamoya disease. J Stroke Cerebrovasc Dis. 2017;26(5):1088–97.

    Article  PubMed  Google Scholar 

  7. Gross BA, Du R. The natural history of moyamoya in a North American adult cohort. J Clin Neurosci. 2013;20(1):44–8.

    Article  PubMed  Google Scholar 

  8. Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. J Neurosurg. 2009;111:927–35. (Clinical article)

    Article  PubMed  Google Scholar 

  9. Acker G, Goerdes S, Schmiedek P, Czabanka M, Vajkoczy P. Characterization of clinical and radiological features of quasi-moyamoya disease among European Caucasians including surgical treatment and outcome. Cerebrovasc Dis. 2016;42(5–6):464–75.

    Article  PubMed  Google Scholar 

  10. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008;79(8):900–4.

    Article  CAS  PubMed  Google Scholar 

  11. Duan L, Bao XY, Yang WZ, Shi WC, Li DS, Zhang ZS, et al. Moyamoya disease in China: its clinical features and outcomes. Stroke. 2012;43(1):56–60.

    Article  PubMed  Google Scholar 

  12. Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke. 2007;38(5):1430–5.

    Article  PubMed  Google Scholar 

  13. Ikezaki K, Han DH, Kawano T, Inamura T, Fukui M. Epidemiological survey of moyamoya disease in Korea. Clin Neurol Neurosurg. 1997;99(Suppl 2):S6–10.

    Article  PubMed  Google Scholar 

  14. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS. Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study. Stroke. 2014;45(4):1090–5.

    Article  PubMed  Google Scholar 

  15. Kim T, Lee H, Bang JS, Kwon OK, Hwang G. Oh CW. Epidemiology of moyamoya disease in Korea: based on National Health Insurance Service data. J Korean Neurosurg Soc. 2015;57(6):390–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington state and California. Neurology. 2005;65(6):956–8.

    Article  PubMed  Google Scholar 

  17. Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P. Clinical presentation of moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. J Neurol. 2019;266(6):1421–8.

    Article  PubMed  Google Scholar 

  18. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet. 2007;15(2):131–8.

    Article  CAS  PubMed  Google Scholar 

  19. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke. 1993;24(12):1960–7.

    Article  CAS  PubMed  Google Scholar 

  20. Cairns AG, North KN. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry. 2008;79(10):1165–70.

    Article  CAS  PubMed  Google Scholar 

  21. Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol. 2013;28(1):95–101.

    Article  PubMed  Google Scholar 

  22. Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology. 2005;64(3):553–5.

    Article  PubMed  Google Scholar 

  23. Bajaj A, Li QF, Zheng Q, Pumiglia K. Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS One. 2012;7(11):e49222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Fukushima Y, Kondo Y, Kuroki Y, Miyake S, Iwamoto H, Sekido K, et al. Are down syndrome patients predisposed to moyamoya disease? Eur J Pediatr. 1986;144(5):516–7.

    Article  CAS  PubMed  Google Scholar 

  25. Panegyres PK, Morris JG, O'Neill PJ, Balleine R. Moyamoya-like disease with inflammation. Eur Neurol. 1993;33(3):260–3.

    Article  CAS  PubMed  Google Scholar 

  26. Chastain MA, Russo GG, Boh EE, Chastain JB, Falabella A, Millikan LE. Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature. J Am Acad Dermatol. 1999;41(5 Pt 1):757–64.

    Article  CAS  PubMed  Google Scholar 

  27. Colleran KM, Ratliff DM, Burge MR. Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events. Endocr Pract. 2003;9(4):290–5.

    Article  PubMed  Google Scholar 

  28. Santoro JD, Lee S, Mlynash M, Nguyen T, Lazzareschi DV, Kraler LD, et al. Blood pressure elevation and risk of moyamoya syndrome in patients with trisomy 21. Pediatrics. 2018;142(4):e20180840.

    Article  PubMed  Google Scholar 

  29. Kim SJ, Heo KG, Shin HY, Bang OY, Kim GM, Chung CS, et al. Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke. 2010;41(1):173–6.

    Article  PubMed  Google Scholar 

  30. Ohba S, Nakagawa T, Murakami H. Concurrent Graves’ disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment. Neurosurg Rev. 2011;34(3):297–304. discussion

    Article  PubMed  Google Scholar 

  31. Weng L, Cao X, Han L, Zhao H, Qiu S, Yan Y, et al. Association of increased Treg and Th17 with pathogenesis of moyamoya disease. Sci Rep. 2017;7(1):3071.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Soliman M, Kaplan E, Yanagawa T, Hidaka Y, Fisfalen ME, De Groot LJ. T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. J Clin Endocrinol Metab. 1995;80(3):905–14.

    CAS  PubMed  Google Scholar 

  33. Nakamura K, Yanaka K, Ihara S, Nose T. Multiple intracranial arterial stenoses around the circle of Willis in association with Graves’ disease: report of two cases. Neurosurgery. 2003;53(5):1210–4. discussion 4–5

    Article  PubMed  Google Scholar 

  34. Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves’ disease: special considerations regarding clinical significance and management. J Neurosurg. 2005;102(6):1013–7.

    Article  PubMed  Google Scholar 

  35. Golomb MR, Biller J, Smith JL, Edwards-Brown M, Sanchez JC, Nebesio TD, et al. A 10-year-old girl with coexistent moyamoya disease and Graves’ disease. J Child Neurol. 2005;20(7):620–4.

    Article  PubMed  Google Scholar 

  36. Cohen N, Berant M, Simon J. Moyamoya and Fanconi's anemia. Pediatrics. 1980;65(4):804–5.

    CAS  PubMed  Google Scholar 

  37. Tsuruta D, Fukai K, Seto M, Fujitani K, Shindo K, Hamada T, et al. Phakomatosis pigmentovascularis type IIIb associated with moyamoya disease. Pediatr Dermatol. 1999;16(1):35–8.

    Article  CAS  PubMed  Google Scholar 

  38. Murphy ES, Xie H, Merchant TE, Yu JS, Chao ST, Suh JH. Review of cranial radiotherapy-induced vasculopathy. J Neuro-Oncol. 2015;122(3):421–9.

    Article  CAS  Google Scholar 

  39. Rea D, Brandsema JF, Armstrong D, Parkin PC, deVeber G, MacGregor D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124(3):e476–83.

    Article  PubMed  Google Scholar 

  40. Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007;68(12):932–8.

    Article  CAS  PubMed  Google Scholar 

  41. Titsworth WL, Scott RM, Smith ER. National Analysis of 2454 pediatric moyamoya admissions and the effect of hospital volume on outcomes. Stroke. 2016;47(5):1303–11.

    Article  PubMed  Google Scholar 

  42. Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ. Moyamoya syndrome associated with neurofibromatosis type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013;11(4):417–25.

    Article  PubMed  Google Scholar 

  43. Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143(5):e20190660.

    Article  PubMed  Google Scholar 

  44. Karousou E, Stachtea X, Moretto P, Viola M, Vigetti D, D’Angelo ML, et al. New insights into the pathobiology of down syndrome--hyaluronan synthase-2 overexpression is regulated by collagen VI α2 chain. FEBS J. 2013;280(10):2418–30.

    Article  CAS  PubMed  Google Scholar 

  45. Kainth DS, Chaudhry SA, Kainth HS, Suri FK, Qureshi AI. Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery. 2013;72(2):210–5. discussion 5

    Article  PubMed  Google Scholar 

  46. Jea A, Smith ER, Robertson R, Scott RM. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics. 2005;116(5):e694–701.

    Article  PubMed  Google Scholar 

  47. Liu JS, Juo SH, Chen WH, Chang YY, Chen SS. A case of graves’ diseases associated with intracranial moyamoya vessels and tubular stenosis of extracranial internal carotid arteries. J Formos Med Assoc. 1994;93(9):806–9.

    CAS  PubMed  Google Scholar 

  48. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J. 2000;47(4):467–70.

    Article  CAS  PubMed  Google Scholar 

  49. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004;109(22):2766–72.

    Article  CAS  PubMed  Google Scholar 

  50. Kushima K, Satoh Y, Ban Y, Taniyama M, Ito K, Sugita K. Graves’ thyrotoxicosis and moyamoya disease. Can J Neurol Sci. 1991;18(2):140–2.

    Article  CAS  PubMed  Google Scholar 

  51. Tendler BE, Shoukri K, Malchoff C, MacGillivray D, Duckrow R, Talmadge T, et al. Concurrence of Graves’ disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid. 1997;7(4):625–9.

    Article  CAS  PubMed  Google Scholar 

  52. Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9):3144–50.

    Article  CAS  PubMed  Google Scholar 

  53. Kauv P, Gaudré N, Hodel J, Tuilier T, Habibi A, Oppenheim C, et al. Characteristics of moyamoya syndrome in sickle-cell disease by magnetic resonance angiography: an adult-cohort study. Front Neurol. 2019;10:15.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Kennedy BC, McDowell MM, Yang PH, Wilson CM, Li S, Hankinson TC, et al. Pial synangiosis for moyamoya syndrome in children with sickle cell anemia: a comprehensive review of reported cases. Neurosurg Focus. 2014;36(1):E12.

    Article  PubMed  Google Scholar 

  55. Matsuki Y, Kawakami M, Ishizuka T, Kawaguchi Y, Hidaka T, Suzuki K, et al. SLE and Sjögren’s syndrome associated with unilateral moyamoya vessels in cerebral arteries. Scand J Rheumatol. 1997;26(5):392–4.

    Article  CAS  PubMed  Google Scholar 

  56. Tsuda H, Hattori S, Tanabe S, Nishioka S, Matsushima T, Ikezaki K, et al. Thrombophilia found in patients with moyamoya disease. Clin Neurol Neurosurg. 1997;99(Suppl 2):S229–33.

    Article  PubMed  Google Scholar 

  57. Booth F, Yanofsky R, Ross IB, Lawrence P, Oen K. Primary Antiphospholipid syndrome with Moyamoya-like vascular changes. Pediatr Neurosurg. 1999;31(1):45–8.

    Article  CAS  PubMed  Google Scholar 

  58. Shanahan P, Hutchinson M, Bohan A, O’Donoghue D, Sheahan K, Owens A. Hemichorea, Moya-Moya, and ulcerative colitis. Mov Disord. 2001;16(3):570–2.

    Article  CAS  PubMed  Google Scholar 

  59. Kotagal S, Peterson PL, Martens ME, Lee CP, Nigro M, Archer CR. Impaired NADH-CoQ reductase activity in a child with moyamoya syndrome. Pediatr Neurol. 1988;4(4):241–4.

    Article  CAS  PubMed  Google Scholar 

  60. van Diemen-Steenvoorde R, van Nieuwenhuizen O, de Klerk JB, Duran M. Quasi-moyamoya disease and heterozygosity for homocystinuria in a five-year-old girl. Neuropediatrics. 1990;21(2):110–2.

    Article  PubMed  Google Scholar 

  61. Keene DL, Johnston DL, Grimard L, Michaud J, Vassilyadi M, Ventureyra E. Vascular complications of cranial radiation. Childs Nerv Syst. 2006;22(6):547–55.

    Article  PubMed  Google Scholar 

  62. Morris B, Partap S, Yeom K, Gibbs IC, Fisher PG, King AA. Cerebrovascular disease in childhood cancer survivors: a children’s oncology group report. Neurology. 2009;73(22):1906–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Desai SS, Paulino AC, Mai WY, Teh BS. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys. 2006;65(4):1222–7.

    Article  PubMed  Google Scholar 

  64. Reynolds MR, Haydon DH, Caird J, Leonard JR. Radiation-induced moyamoya syndrome after proton beam therapy in the pediatric patient: a case series. Pediatr Neurosurg. 2016;51(6):297–301.

    Article  PubMed  Google Scholar 

  65. Czartoski T, Hallam D, Lacy JM, Chun MR, Becker K. Postinfectious vasculopathy with evolution to moyamoya syndrome. J Neurol Neurosurg Psychiatry. 2005;76(2):256–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Dhawan SR, Sahu JK, Vyas S, Singhi SC, Singhi PD. Pyogenic meningitis complicated with extensive central nervous system vasculitis and moyamoya vasculopathy. J Pediatr Neurosci. 2018;13(3):343–5.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Jeon JP, Kim JE, Cho WS, Bang JS, Son YJ, Oh CW. Meta-analysis of the surgical outcomes of symptomatic moyamoya disease in adults. J Neurosurg. 2018;128(3):793–9.

    Article  PubMed  Google Scholar 

  68. Horn P, Pfister S, Bueltmann E, Vajkoczy P, Schmiedek P. Moyamoya-like vasculopathy (moyamoya syndrome) in children. Childs Nerv Syst. 2004;20(6):382–91.

    Article  PubMed  Google Scholar 

  69. Smith ER, Scott RM. Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus. 2008;24(2):E17.

    Article  PubMed  Google Scholar 

  70. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 2003;29(2):124–30.

    Article  PubMed  Google Scholar 

  71. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56(1):34–40.

    Article  CAS  PubMed  Google Scholar 

  72. Hervé D, Philippi A, Belbouab R, Zerah M, Chabrier S, Collardeau-Frachon S, et al. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet. 2014;94(3):385–94.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Miskinyte S, Butler MG, Hervé D, Sarret C, Nicolino M, Petralia JD, et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet. 2011;88(6):718–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Charité–Universitätsmedizin Berlin (corporate member of Freie Universität Berlin, Humboldt–Universität zu Berlin, and Berlin Institute of Health), Berlin, Germany

    Kristin Lucia, Güliz Acker & Peter Vajkoczy

Authors
  1. Kristin Lucia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Güliz Acker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Vajkoczy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Vajkoczy .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan

    Satoshi Kuroda

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lucia, K., Acker, G., Vajkoczy, P. (2021). Moyamoya Syndrome. In: Kuroda, S. (eds) Moyamoya Disease: Current Knowledge and Future Perspectives. Springer, Singapore. https://doi.org/10.1007/978-981-33-6404-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-33-6404-2_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-33-6403-5

  • Online ISBN: 978-981-33-6404-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation